Vincristine, dexamethasone and epratuzumab for older relapsed/refractory CD22(+) B-acute lymphoblastic leukemia patients: a phase II study

類似資料

• Hyper-CVAD + epratuzumab as a salvage regimen for younger patients with relapsed/refractory CD22-positive precursor B-cell acute lymphocytic leukemia
  著者:: Chevallier, Patrice, 等
  出版事項: (2017)
• Adverse prognostic significance of CD20 expression in adults with Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia
  著者:: Maury, Sébastien, 等
  出版事項: (2010)
• L-asparaginase for adult CD20 positive B-cell precursor acute lymphoblastic leukemia
  著者:: Maury, Sébastien, 等
  出版事項: (2010)
• Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus
  著者:: Dörner, Thomas, 等
  出版事項: (2006)
• Correction: Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus
  著者:: Dörner, Thomas, 等
  出版事項: (2008)